Related Articles
Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Thursday, June 27th, ThisIsMoney.Co.Uk reports.
A number of other equities research analysts also recently issued reports on the company. Deutsche Bank reduced their price target on from GBX 217 ($2.84) to GBX 175 ($2.29) and set a sell rating on the stock in a research report on Monday, June 24th. Liberum Capital assumed coverage on in a research report on Monday, June 17th. They set a buy rating and a GBX 60 ($0.78) price target on the stock. Credit Suisse Group reaffirmed a sell rating and issued a $6.50 target price on shares of Deutsche Bank in a report on Monday, April 29th. JPMorgan Chase & Co. raised ROYAL MAIL PLC/ADR from an underweight rating to a neutral rating in a report on Monday, June 3rd. Finally, UBS Group upgraded to a neutral rating and increased their price target for the company from GBX 945 ($12.35) to GBX 2,060 ($26.92) in a research note on Thursday, June 20th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of GBX 6,502.94 ($84.97).
LON:AZN traded down GBX 12 ($0.16) during trading hours on Thursday, reaching GBX 6,390 ($83.50). 1,748,279 shares of the company were exchanged, compared to its average volume of 2,310,000. The firm has a market capitalization of $83.82 billion and a P/E ratio of 33.63. AstraZeneca has a 1-year low of GBX 5,312 ($69.41) and a 1-year high of GBX 6,634 ($86.68). The company has a debt-to-equity ratio of 179.66, a current ratio of 0.75 and a quick ratio of 0.57. The firm has a 50 day moving average of GBX 6,299.76.
In related news, insider Marc Dunoyer purchased 8,500 shares of the business’s stock in a transaction on Tuesday, May 7th. The stock was acquired at an average price of GBX 5,800 ($75.79) per share, for a total transaction of £493,000 ($644,191.82). Also, insider Philip A. J. Broadley purchased 520 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were bought at an average price of GBX 5,738 ($74.98) per share, with a total value of £29,837.60 ($38,988.11).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: How interest rates affect municipal bond prices
Receive News & Ratings for AstraZeneca Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AstraZeneca and related companies with MarketBeat.com’s FREE daily email newsletter.
Source link
